论文部分内容阅读
目的:体外研究清开灵注射液对人血清补体和RBL-2 H3细胞的影响。方法:采用ELISA法检测清开灵注射液对人血清补体末端复合物SC5 b-9含量的影响。将不同批号、不同浓度的清开灵注射液与RBL-2 H3细胞共孵育,作用45 min后,显微镜下观察细胞脱颗粒,显色法测定β-氨基己糖苷酶释放度和ELISA法测定组胺释放量。结果:清开灵注射液能使人血清中SC5 b-9含量降低,与PBS组比较,差异有统计学意义(P<0.05);能刺激RBL-2 H3细胞释放组胺和β-氨基己糖苷酶,与阴性组比较,差异具有统计学意义(P<0.05)。结论:清开灵注射液不能引起补体系统激活,可以直接刺激肥大细胞脱颗粒释放组胺和β-氨基己糖苷酶。其在临床引起的不良反应可能为非补体激活相关的类过敏反应。
Objective: To study the effect of Qingkailing injection on human serum complement and RBL-2 H3 cells in vitro. Methods: The effect of Qingkailing injection on the content of human serum complement end complex SC5 b-9 was detected by ELISA. Different batches and different concentrations of Qingkailing injection were incubated with RBL-2 H3 cells for 45 min, the cells were observed under a microscope degranulation, colorimetric determination of beta-hexosaminidase release and ELISA assay group Amine release. Results: Qingkailing injection could decrease the content of SC5 b-9 in human serum, which was significantly different from PBS group (P <0.05). It could stimulate the release of histamine and β-aminohexyl group in RBL-2 H3 cells Glycosidase, compared with the negative group, the difference was statistically significant (P <0.05). Conclusion: Qingkailing injection can not cause activation of complement system and can directly stimulate mast cells degranulation to release histamine and β-hexosaminidase. Its clinical adverse reactions may be non-complement activation-related allergic reactions.